P2673Challenging time limits: Using a single high-sensitive troponin I to rule-out acute myocardial infarction in early presenters
| العنوان: | P2673Challenging time limits: Using a single high-sensitive troponin I to rule-out acute myocardial infarction in early presenters |
|---|---|
| المؤلفون: | Christian Alcaraz Frederiksen, Nete Hornung, B Loefgren, Camilla Hansen, Tage Jensen, Camilla Bang, Kasper G Lauridsen, Michael Schmidt |
| المصدر: | European Heart Journal. 40 |
| بيانات النشر: | Oxford University Press (OUP), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, biology, business.industry, Chest pain, medicine.disease, Troponin, Internal medicine, High sensitivity troponin, Hospital admission, Troponin I, medicine, Cardiology, biology.protein, Myocardial infarction, medicine.symptom, Cardiology and Cardiovascular Medicine, business |
| الوصف: | Introduction According to ESC guidelines, an acute myocardial infarction (MI) can be excluded without serial troponin measurements in patients presenting with a single high-sensitive troponin below the 99th percentile and chest pain starting >6 hours prior to admission. However, it is unclear if single-testing of high-sensitive troponin can rule-out MI in early presenters. Purpose To investigate the diagnostic performance of a single value of high-sensitive cardiac troponin I (hs-cTnI) at presentation for ruling-out MI in patients presenting with chest pain to the Emergency Department irrespective of chest pain onset. Methods We conducted a substudy of preliminary data from the RACING-MI trial. We included patients presenting with chest pain suggestive of MI to the Emergency Department of a Regional Hospital. We used the Siemens hs-cTnI (Siemens Healthcare, TNIH, Limit of detection: 2.21 ng/L) and a diagnostic cut-off value 6 hours). Results We included 989 patients with available hs-cTnI results at admission. MI was confirmed in 82 (8.3%) patients. Using hs-cTnI Based on chest pain onset, 33.8% of patients were classified as very early, 12.8% as early, and 42.7% as late presenters, with 10.7% patients with unreported/unknown onset. NPV was 100% (95% CI 96.5–100) for very early, 100% (95% CI 88.3–100) for early and 100% (95% CI 97.3–100) for late presenters. Conclusions Using a single hs-cTnI value ClinicalTrials.gov Identifier: NCT03634384. Acknowledgement/Funding Randers Regional Hospital, A.P Møller Foundation, Boserup Foundation, Korning Foundation, Højmosegård Grant, Siemens Healthcare (TNIH assays), etc. |
| تدمد: | 1522-9645 0195-668X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::321c3ea741512541dc4f73ebd5134dfb https://doi.org/10.1093/eurheartj/ehz748.0991 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........321c3ea741512541dc4f73ebd5134dfb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15229645 0195668X |
|---|